| 580 | 12 | 137 |
| 下载次数 | 被引频次 | 阅读次数 |
持续性异位妊娠是异位妊娠药物治疗或输卵管开窗手术治疗术后常见并发症之一,主要原因是治疗未能完全清除滋养细胞。近20年单一剂量MTX治疗输卵管异位妊娠初次成功率约54%~90%,发生的概率约为10%~45%;异位妊娠输卵管开窗术后发生持续性异位妊娠的概率为5%~20%。如何预测持续性异位妊娠及其高危因素,以及如何治疗持续性异位妊娠成为了热点话题,本文对于持续性异位妊娠的临床诊治及预防进展予以综述。
Abstract：Persistent ectopic pregnancy is one of the common complications of ectopic pregnancy drug therapy or conservative surgery,mainly due to failure to completely remove trophoblastic tissue.Statistics results from nearly 20 years shows that the success rate of a single-dose MTX initial treatment was about 54%-90%,and the occurrence of persistent ectopic pregnancy rate was about 10%-45%.The occurrence rate of persistent ectopic pregnancy after ectopic pregnancy conservative surgery was about 5%-20%.How to predict the occurrence of persistent ectopic pregnancy and how to treat persistent ectopic pregnancy have become a hot topic.This article reviews the clinical management of persistent ectopic pregnancy.
[1]Barnhart KT.Clinical practice.Ectopic pregnancy[J].N Engl J Med,2009,361:379-387.
[2]Newbatt E,Beckles Z,Ullman R,et al.Ectopic pregnancy and miscarriage:summary of NICE guidance[J].BMI,2012,345:e8136.
[3]Whitehouse B.Salpingotomy versus salpingectomy in the treatment of tubal gestation[J].Proc R Soc Med,1922,15:17-22.
[4]Buster JE,Carson SA.Ectopic pregnancy:new advances in diagnosis and treatment[J].Curr Opin Obstet Gynecol,1995,7:168-176.
[5]Graczykowski JW,Mishell DR,Jr.Methotrexate prophylaxis for persistent ectopic pregnancy after conservative treatment by salpingostomy[J].Obstet Gynecol,1997,89:118-122.
[6]Hoppe DE,Bekkar BE,Nager CW.Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery[J].Obstet Gynecol,1994,83:51-54.
[7]Bengtsson G,Bryman I,Thorburn J,et al.Low-dose oral methotrexate as second-line therapy for persistent trophoblast after conservative treatment of ectopic pregnancy[J].Obstet Gynecol,1992,79:589-591.
[8]Thornton KL,Diamond MP,DeCherney AH.Linear salpingostomy for ectopic pregnancy[J].Obstet Gynecol Clin North Am,1991,18:95-109.
[9]Stovall TG,Ling FW.Single-dose methotrexate:an expanded clinical trial[J].Am J Obstet Gynecol,1993,168:1759-1762.
[10]Hajenius PJ,Mol BW,Ankum WM,et al.Clearance curves of serum human chorionic gonadotrophin for the diagnosis of persistent trophoblast[J].Hum Reprod,1995,10:683-687.
[11]Girija S,Manjunath AP,Salahudin A,et al.Role of day 4HCG as an early predictor of success after methotrexate therapy for ectopic pregnancies[J].Eur J Obstet Gynecol Reprod Biol,2017,215:230-233.
[12]Stovall TG,Ling FW,Gray LA.Single-dose methotrexate for treatment of ectopic pregnancy[J].Obstet Gynecol,1991,77:754-757.
[13]Ozyurek ES,Akmut E,Kaya E,et al.Predictors of failure of the commonly used single-dose methotrexate protocol for treating tubal ectopic pregnancies[J].Taiwan J Obstet Gynecol,2017,56:755-760.
[14]Kovaleva A,Irishina N,Pereira A,et al.Methotrexate-treated ectopic pregnancy:beta human chorionic gonadotropin serum changes as a success predictor using a mathematical model validation[J].Eur J Obstet Gynecol Reprod Biol,2017,210:35-38.
[15]Atkinson M,Gupta S,McGee T.betahCG monitoring after single-dose methotrexate treatment of tubal ectopic pregnancy:is the Day 4betahCG necessary?A retrospective cohort study[J].Aust N Z J Obstet Gynaecol,2014,54:475-479.
[16]Sukur YE,Koyuncu K,Seval MM,et al.Comparison of alternative betahCG follow-up protocols after single-dose methotrexate therapy for tubal ectopic pregnancy[J].Arch Gynecol Obstet,2017,296:1161-1165.
[17]Dai Y,Zhang G,Zhu L,et al.Routine beta-Human Chorionic Gonadotropin Monitoring for Single-Dose Methotrexate Treatment in Ectopic Pregnancy[J].J Minim Invasive Gynecol,2017,24:1195-1199.
[18]Levin G,Saleh NA,Haj-Yahya R,et al.Predicting success of methotrexate treatment by pretreatmentHCGlevel and 24-hour HCG increment[J].Int J Gynaecol Obstet,2017,61:1-4.
[19]Mock P,Chardonnens D,Stamm P,et al.The apparent late half-life of human chorionic gonadotropin(hCG)after surgical treatment for ectopic pregnancy.A new approach to diagnose persistent trophoblastic activity[J].Eur J Obstet Gynecol Reprod Biol,1998,78:99-102.
[20]Billieux MH,Petignat P,Anguenot JL,et al.Early and late half-life of human chorionic gonadotropin as a predictor of persistent trophoblast after laparoscopic conservative surgery for tubal pregnancy[J].Acta Obstet Gynecol Scand,2003,82:550-555.
[21]Lund CO,Nilas L,Bangsgaard N,et al.Persistent ectopic pregnancy after linear salpingotomy:a non-predictable complication to conservative surgery for tubal gestation[J].Acta Obstet Gynecol Scand,2002,81:1053-1059.
[22]Jurkovic D,Memtsa M,Sawyer E,et al.Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy:aplacebo-controlled randomized trial[J].Ultrasound Obstet Gynecol,2017,49:171-176.
[23]van Mello NM,Mol F,Verhoeve HR,et al.Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations?A randomized comparison[J].Hum Reprod,2013,28:60-67.
[24]Sendy F,AlShehri E,AlAjmi A,et al.Failure rate of single dose methotrexate in managment of ectopic pregnancy[J].Obstet Gynecol Int,2015,2015:902426.
[25]Bonin L,Pedreiro C,Moret S,et al.Predictive factors for the methotrexate treatment outcome in ectopic pregnancy:A comparative study of 400cases[J].Eur J Obstet Gynecol Reprod Biol,2017,208:23-30.
[26]Mol F,van Mello NM,Strandell A,et al.Salpingotomy versus salpingectomy in women with tubal pregnancy(ESEP study):an open-label,multicentre,randomised controlled trial[J].Lancet,2014,383:1483-1489.
[27]Helmy S,Bader Y,Pablik E,et al.Cut-off value of initial serum beta-hCG level predicting a successful MTX therapy in tubal ectopic pregnancy:a retrospective cohort study[J].Eur J Obstet Gynecol Reprod Biol,2014,179:175-180.
[28]Sowter MC,Farquhar CM,Petrie KJ,et al.A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy[J].BJOG,2001,108:192-203.
[29]Seifer DB,Gutmann JN,Grant WD,et al.Comparison of persistent ectopic pregnancy after laparoscopic salpingostomy versus salpingostomy at laparotomy for ectopic pregnancy[J].Obstet Gynecol,1993,81:378-382.
[30]Fernandez H,Capmas P,Lucot JP,et al.Fertility after ectopic pregnancy:the DEMETER randomized trial[J].Hum Reprod,2013,28:1247-1253.
[31]Mol F,Mol BW,Ankum WM,et al.Current evidence on surgery,systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy:a systematic review and meta-analysis[J].Hum Reprod Update,2008,14:309-319.
[32]Akira S,Negishi Y,Abe T,et al.Prophylactic intratubal injection of methotrexate after linear salpingostomy for prevention of persistent ectopic pregnancy[J].J Obstet Gynaecol Res,2008,34:885-889.
[33]Alge AA,Martin J,Muller-Holzner E,et al.Uncommon location of persistent ectopic pregnancy following laparoscopic surgery[J].Obstet Gynecol,1994,84:697-698.
[34]Mol F,van Mello NM,Strandell A,et al.Cost-effectiveness of salpingotomy and salpingectomy in women with tubal pregnancy(a randomized controlled trial)[J].Hum Reprod,2015,30:2038-2047.
[35]Wu MC,Huang WC,Lin HH,et al.Severe intra-abdominal bleeding from neglected omental implantation of ectopic tissue after methotrexate treatment for persistent ectopic pregnancy[J].Fertil Steril,2011,95:2435e1-2345e3.
[36]Ben-Arie A,Goldchmit R,Dgani R,et al.Trophoblastic peritoneal implants after laparoscopic treatment of ectopic pregnancy[J].Eur J Obstet Gynecol Reprod Biol,2001,96:113-115.
基本信息:
中图分类号:R713.8
引用信息:
[1]王丹莹,刘海元.持续性异位妊娠的临床诊治进展[J].生殖医学杂志,2018,27(08):809-813.
2018-08-15
2018-08-15